InsurTech Valuation

The global insurtech sector enters 2025 in a more mature and more sober state than at any point in the last cycle. After the “Great Correction” of 2022–2023, when funding volumes fell by more than half, the market has settled into a steadier “New Normal.” By Q3 2025, global insurtech funding has held at roughly $1.1 billion per quarter for eleven straight quarters, which points to a healthier capital environment, disciplined, but still active.

Total invested capital in insurtech since 2012 has reached about $60 billion, but the way money is being allocated has changed materially. Series A and B rounds have dropped roughly 50% year over year as investors shift from momentum to quality and efficiency. At the same time, strategic participation has surged: in Q3 2025 alone, (re)insurers backed 51 tech investments. Valuation outcomes now look clearly split. “AI-native” insurers and B2B SaaS infrastructure players are still getting software-like multiples, roughly 15x to 30x, while capital-intensive carriers are valued more like insurance companies, typically around 1x to 3x, anchored to public comparables.

This report focuses on how valuation is being set in practice, why M&A is back as the primary exit path, and which operating metrics now decide whether a company earns a premium. The gatekeepers are no longer narrative-driven, Net Dollar Retention, loss-ratio stability, and repeatable underwriting performance increasingly determine who gets rewarded. In short, the sector has moved past “growth at all costs” and into an era where profitability and precision do the heavy lifting.

What Multiples Do Investors Use to Value Insurtech Companies?

The Shift from Gross Written Premium to Net Revenue

The most important methodological change in 2025 is that investors have tightened their definition of revenue. Gross Written Premium is no longer treated as a credible basis for valuation in most deals; it’s widely viewed as a volume metric, not a value metric. Instead, the market has shifted toward Net Revenue, Net Commission for MGAs, or Earned Premium minus reinsurance and claims for carriers. That shift reflects a more industrialized market: investors are paying for retained economics and unit-level durability, not just throughput.

For early-stage and high-growth insurtechs (Series A through Series C), revenue multiples remain the shorthand most commonly used, but the dispersion is much wider than it used to be, and it tracks business model more than headline growth. Pure technology companies and AI-native firms can separate from traditional insurance comp sets, while digital carriers tend to get pulled back toward public insurance comparables.

Bifurcation of Valuation Tiers

A practical tiering system has taken hold. Tier 1 companies, primarily B2B SaaS infrastructure and AI-native platforms, often trade between 15x and 30x net revenue. The market treats them like enterprise software: 80%+ gross margins, scalable delivery, and expanding operating leverage.

Tier 2 is dominated by tech-enabled MGAs, which more commonly land in the 3x to 8x net revenue range. Their margins are lower than pure SaaS, commissions are typically 20% to 30%. but they generally avoid balance-sheet risk. If they can show strong ROE and clean unit economics, they still earn a meaningful premium relative to carriers.

Tier 3 includes capital-intensive digital carriers and brokerages, frequently valued around 1.5x to 3.5x net revenue. These businesses face real capital drag and regulatory surplus requirements, which constrain multiples. Public-market reference points reinforce the split: public insurtechs often trade in the 6x to 10x range, while private markets can still award higher premiums where growth quality and differentiation are clear.

Table 1: Valuation Multiples by Company Stage (2025 Benchmarks)

Source: Gallagher Re Global InsurTech Report Q3 2025, Finro Financial Consulting: Insurtech Valuation Multiples 2025.

How Does Insurtech Valuation Differ from Traditional Insurance?

The Technology Premium vs. The Balance Sheet Penalty

The “valuation gap” remains a defining feature of 2025. Investors have gotten much sharper about separating software economics from balance-sheet economics. Even with the “tech” label, companies that carry underwriting risk get valued differently than those that sell software or operate asset-light models. The gap versus top public fintech valuations remains large, driven by basic scaling physics. Payments and banking infrastructure can scale with close to zero marginal cost; insurance scales with capital, surplus, and claims variability.

Traditional insurers are still valued primarily on Book Value multiples and ROE because they are asset-heavy businesses. Insurtechs, particularly MGAs and SaaS providers, try to avoid that gravitational pull by proving they are genuinely asset-light. Full-stack carriers, however, are increasingly anchored to traditional ranges (often 1x to 1.5x Book Value) unless they can demonstrate real operational leverage, scaling premiums without needing a matching increase in headcount, often with AI as the enabling mechanism.

Reinsurance as a Valuation Lever

Insurtech carriers also use reinsurance differently than incumbents. For many, it’s not just risk management, it’s a capital-efficiency tool. Quota share arrangements can reduce capital requirements and improve ROE, which in theory supports higher multiples. The catch is that this lever has gotten harder to pull: reinsurance has become more expensive and capacity providers are more selective. In practice, a diversified panel of A-rated reinsurers increasingly functions as a credibility moat. It stabilizes capacity, reduces dependency on a single partner, and lowers the perceived “key counterparty” risk that can otherwise weigh on valuation.

Table 2: Revenue Multiple Comparisons by Sector

Source: Finro Financial Consulting: Insurtech Valuation Multiples 2025, McKinsey Global Private Markets Report 2025.

What Metrics Matter Most in Insurtech Valuation?

The Primacy of Loss Ratio Stability

In today’s market, “quality of revenue” is defined first and foremost by loss-ratio control, and by consistency. Investors will often pay more for a business with a steady 65% loss ratio than for one that swings between 50% and 90%. Volatility reads as weak underwriting control, unclear risk selection, or an immature pricing model. For companies aiming at premium valuations, a gross loss ratio in the 40% to 60% range, well ahead of industry averages, has become one of the cleanest proof points of underwriting alpha and model efficacy.

Combined ratio discipline matters just as much. With industry combined ratios often cited around the low 90s, insurtechs running above 100% (unprofitable underwriting) face steep discounts. For Series B+ companies, investors increasingly want to see a credible path to sub-95% combined ratios within roughly 24 months.

Unit Economics and Retention

Beyond underwriting, SaaS-style diligence has fully arrived. Net Dollar Retention is now a gating metric for premium multiples in B2B insurtech. NDR above 120% signals true product stickiness and upsell potential, important if you’re arguing for 15x+ revenue multiples.

For B2C models, the discussion shifts toward CAC efficiency and payback discipline. An LTV:CAC ratio of 3:1 is generally viewed as baseline; the strongest valuations tend to require 5:1+ with CAC payback under 12 months, particularly in consumer lines where churn risk can surface quickly.

Table 3: Growth Metric Benchmarks for Premium Valuation

Source: Gallagher Re Global InsurTech Report Q3 2025, Finro Financial Consulting: Insurtech Valuation Multiples 2025.

How Are Embedded Insurance Platforms Valued Differently?

Distribution as a Product

Embedded insurance, where coverage is offered inside someone else’s checkout or booking flow, gets valued under a different playbook than a traditional DTC insurer. In this model, distribution is the asset. Valuations are often built from the ground up using contracted revenue tied to exclusive partnerships (for example, with an OEM, a large e-commerce platform, or a travel marketplace). A signed exclusive arrangement can look less like “marketing-driven growth” and more like an annuity: predictable volume, clearer forecasting, and (usually) a longer customer lifetime than what you can achieve when you’re constantly reacquiring consumers one by one.

Infrastructure vs. Brokerage Valuation

Within embedded, investors draw a hard line between infrastructure businesses and brokerage businesses.

Infrastructure players, such as platforms that let a partner effectively operate a captive program (“captive-as-a-service”), tend to earn higher multiples because they sit closer to the rails. They capture deeper economics, can scale across multiple partners, and become harder to displace once integrated. These businesses often get valued more like fintech infrastructure, commonly in the ~12x–20x range.

Brokerage-style embedded players, by contrast, are primarily monetizing distribution via commissions on policies placed. That’s a real business, but it’s structurally more transactional: margins and defensibility look closer to an agency model, so multiples typically compress to something like ~3x–5x.

Table 4: Embedded Insurance vs. Standalone Insurtech Models

Source: Deloitte Insights: Embedded Insurance, Bain & Company: Embedded Finance.

What Exit Valuations Have Recent Insurtech IPOs Achieved?

The Public Market Resurgence

After the 2022–2023 drawdown, public markets have shown they’ll re-engage with insurtech, if the company can demonstrate a credible path to profitability. The strongest “post-correction” performers have benefited from cleaner combined ratios and visible operating leverage, including the use of automation and AI to take costs out of the model. Importantly, these post-correction valuations are now acting as the practical ceiling for private-market expectations.

That said, the IPO window is still selective. Even when overall IPO activity rebounds, public investors have been clear about what they want: predictability, earnings quality, and a model that can absorb scrutiny quarter after quarter. The old “step-up” from late-stage private pricing to an even higher public valuation has narrowed, which means private valuations need to be defensible on fundamentals before the roadshow starts, not after.

Valuation Anchors from Recent Performance

For late-stage investors, the most useful reference points are still the public names from the 2020/2021 cohort. When those stocks recover, it signals that liquidity is possible again, but only for businesses that can look “insurance-sound” on unit economics while still retaining a tech-like growth profile. Private-market enthusiasm for specialized, AI-native models can remain strong in parallel, but public exits ultimately get anchored to what the listed comp set is willing to support.

Table 5: Recent Public Insurtech Performance Indicators (2024-2025)

Source: S&P Global Market Intelligence: Insurtechs Shine on Wall Street.

When Should Insurtechs Pursue M&A vs IPO?

The M&A Put and Strategic Consolidation

For many Series B+ insurtechs, M&A is increasingly the more realistic exit path, faster to execute, less exposed to public-market volatility, and often more forgiving if the story is strong strategically even when growth is moderating. Another shift worth calling out: the line between “strategic investor” and “strategic buyer” is blurring. Incumbents and large (re)insurers are investing heavily in tech, and in many cases, those investments are effectively underwriting future acquisition options. When they buy, they’re often paying strategic premiums (frequently framed as ~3x–5x revenue) to modernize their stacks through MGAs, distribution technology, or underwriting software.

The IPO Threshold

An IPO can still maximize value, but the requirements are now explicit and, frankly, unforgiving. To be a credible 2025/2026 IPO candidate, companies generally need to show scale (often cited as $200M+ in ARR), near-term EBITDA trajectory (positive within a few quarters of listing), and performance consistent with Rule of 40 expectations.

If you’re in that “in-between” range, say $50M to $100M in revenue, an IPO may introduce more execution risk than upside. In that case, a strategic sale (to a carrier) or a sale to a PE-backed platform (as part of a roll-up) can deliver a cleaner liquidity event with fewer moving parts.

Table 6: M&A vs. IPO Decision Framework

Source: PwC Insurance Deals Outlook 2026, EY Global IPO Trends 2025.

Sources

• McKinsey Global Private Markets Report 2025
• PwC Insurance Deals Outlook 2026
• EY Global IPO Trends 2025
• Gallagher Re Global InsurTech Report Q3 2025
• Deloitte Insights: Embedded Insurance
• Bain & Company: Embedded Finance
• S&P Global Market Intelligence: Insurtechs Shine on Wall Street
• CB Insights Insurtech Trends Q2 2025
• Finro Financial Consulting: Insurtech Valuation Multiples 2025